Star Health and Allied Insurance Company Price Movement Clarification
Star Health clarified that the change in promoter shareholding resulted from the transmission of shares from the estate of Late Mr. Rakesh Jhunjhunwala.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
67 announcements with these filters
Star Health clarified that the change in promoter shareholding resulted from the transmission of shares from the estate of Late Mr. Rakesh Jhunjhunwala.
Star Health filed its shareholding pattern for the quarter ended June 30, 2026. The filing includes updates regarding the transmission of shares from the late Rakesh Jhunjhunwala.
Sitara Partners LLP acquired 7,82,13,958 shares of Star Health via off-market transfer. The promoter group's total shareholding reached 13.2887%.
Star Health scheduled a board meeting for July 29, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Star Health announced the retirement of two Independent Directors. Mr. Utpal Sheth was appointed as an Additional Director.
The Estate of Late Rakesh Jhunjhunwala sold its entire 13.05% stake. The transaction was executed off-market via share transmission.
Star Health delivered strong FY26 performance with 13% Insurance Revenue growth and PAT of ₹911cr. Strategy focuses on retail indemnity expertise and digital-first operations.
Star Health Q4 & FY26 results show improved profitability with FY26 PAT at ₹911 Cr (up 16% YoY). Combined ratio improved to 98.8% from 101.1%.
Star Health delivered FY26 GWP of ₹20,369 Cr (16% YoY growth) with an improved Combined Ratio of 98.8%. Strategy focuses on retail indemnity expertise and digital-first operations.
Star Health reported FY26 GWP of ₹20,369 Cr (up 16% YoY) and PAT of ₹911 Cr. Strategy focuses on digital-first onboarding and proprietary agency network growth.
Star Health Q4 & FY26 presentation shows strong turnaround with FY26 PAT at ₹911 Cr (up 16% YoY) and Combined Ratio improving to 98.8%. Strategy focuses on digital onboarding and proprietary agency expansion.
Star Health delivered strong FY26 performance with GWP growing 16% YoY to ₹20,369 Cr and PAT increasing 16% to ₹911 Cr, supported by improved underwriting profitability and a combined ratio of 98.4%.
Star Health delivered FY26 Net Profit of ₹911 Cr (up 16% YoY) with Insurance Revenue growing 13% to ₹17,999 Cr. Focus remains on digital-first distribution and retail indemnity leadership.
Star Health Q4FY26/FY26 presentation shows a return to underwriting profitability and a 16% YoY increase in Net Profit (IND AS). Strategic focus remains on proprietary channels and digital onboarding.
Star Health delivered strong FY26 performance with PAT growth of 16% and a 45% jump in normalized PAT, driven by retail expansion and improved loss ratios.
Star Health FY26 results show strong profitable growth under IndAS with PAT at ₹911 Cr and Combined Ratio improved to 98.4%. Management maintains a focus on retail indemnity and digital-first strategies.
Star Health reported FY26 Net Profit of ₹911 Cr (up 16% YoY) with GWP reaching ₹20,369 Cr. Strategy focuses on retail indemnity expertise and digital-first customer engagement.
Star Health FY26 results show strong top-line growth and underwriting profitability. Management highlights digital transformation, agency network expansion, and improved claim efficiency as key drivers.
Star Health FY26 results show strong momentum with 13% Insurance Revenue growth and a significantly improved Combined Ratio of 98.4% (IndAS). Strategy focuses on proprietary agency channels and digital onboarding.
Star Health issued a postal ballot notice for shareholder approval on director appointments and remuneration revisions. Voting runs from May 18 to June 16, 2026.
Star Health reported a turnaround in FY26 with underwriting profit of ₹206 Cr and GWP growth of 16% to ₹20,369 Cr. Management focused on profitable retail growth and loss ratio improvement.
Star Health FY26 Investor Presentation reports 13% Revenue growth to ₹17,999 Cr and 16% PAT growth to ₹911 Cr. Strategy focuses on retail indemnity, digital-first onboarding, and expanding the proprietary agency network.
Star Health FY26 results show strong profitable growth under IndAS, with Net Profit up 16% YoY and improved combined ratios across both IndAS and IGAAP frameworks.
Star Health FY26 Earnings Presentation shows a return to profitability with Net Profit (PAT) at ₹911 Cr and strong GWP growth of 16% YoY, driven by proprietary channels and digital onboarding.
Star Health delivered a turnaround in FY26, reporting an underwriting profit of ₹206 crores against a prior loss, despite a Q4 net loss due to mark-to-market equity volatility.
Star Health Q4FY26/FY26 presentation shows a shift to IndAS. FY26 PAT grew 16% YoY to ₹911 Cr with a Combined Ratio improvement to 98.8%. Strategy focuses on proprietary agency growth and digital onboarding.
Star Health FY26 Investor Presentation reports 13% Insurance Revenue growth and a shift to profitability with PAT of ₹911 Cr (up 16% YoY) and Combined Ratio improvement to 98.8%.
Star Health and Allied Insurance Company Limited has amended its Policy on Insider Trading as approved by its Board of Directors on April 28, 2026. The update ensures compliance with SEBI Prohibition of Insider Trading Regulations and includes procedures for fair disclosure of unpublished price sensitive information.
Star Health reported a 16% YoY increase in Profit After Tax to ₹911 Crore for FY26. Gross Written Premium grew 16% to ₹20,369 Crore, while the combined ratio improved to 98.8%. The company maintained its retail health leadership with a 31% market share and achieved a turnaround in underwriting profit to ₹206 Crore.
Star Health and Allied Insurance Company Limited submitted a NIL asset cover disclosure for the quarter ended March 31, 2026. The filing pertains to its listed unsecured non-convertible debentures totaling ₹470 Crore. This compliance filing confirms the security status for outstanding debt instruments across two ISINs.